FDA approves Lilly's Verzenio as first-line endocrine therapy

Eli Lilly and Co. (NYSE:LLY) said FDA approved Verzenio abemaciclib as first-line endocrine therapy in combination with an aromatase inhibitor to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.

The approval was based on the Phase III MONARCH 3 trial (see BioCentury, April 27, 2017)...